Celltrion’s ‘Remsima’ approve from U.S. FDA, challenging KRW 20 trillion market

Celltrion announced acquisition of U.S. sales approval of the first biosimilar antibody Remsima from the U.S. Food and Drug Administration(hereinafter referring to FDA) on April 5(local time).

The FDA particularly approved sales of the drug for every indication the company applied, such as rheumatoid arthritis, ankylosing spondylitis, adult uncreative colitis, child and adult Crohn’s disease, ...